Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × rrCLL × Lymphoid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma 659 Lymphoma, Non-Hodgkin 588 Leukemia, Lymphocytic, Chronic, B-Cell 534 Precursor Cell Lymphoblastic Leukemia-Lymphoma 480 Lymphoma, Follicular 415 Lymphoma, Large B-Cell, Diffuse 375 Leukemia 357 Hodgkin Disease 350 Lymphoma, Mantle-Cell 305 Leukemia, Myeloid, Acute 246 Multiple Myeloma 232 Myelodysplastic Syndromes 212 Lymphoma, B-Cell, Marginal Zone 194 Recurrence 193 Burkitt Lymphoma 189 Waldenstrom Macroglobulinemia 154 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 128 Lymphoma, B-Cell 126 Neoplasms 117 Lymphoma, T-Cell, Cutaneous 116 Lymphoma, Large-Cell, Anaplastic 113 Hematologic Neoplasms 102 Lymphoma, Large-Cell, Immunoblastic 100 Mycosis Fungoides 95 Myeloproliferative Disorders 93 Sezary Syndrome 86 Lymphoma, T-Cell, Peripheral 82 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 81 Lymphoma, T-Cell 74 Primary Myelofibrosis 70

Interventions

pembrolizumab 1 dinaciclib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02684617 2021-03-01

KEYNOTE-155

Merck Sharp & Dohme LLC

Phase 1 Terminated

75 enrolled 17 charts

rrCLL

Data powered by HemOnc (CC BY 4.0) Colophon ⚡